CBCSG006_2B: CBCSG006, figure 2B

CBCSG006_2BR Documentation

CBCSG006, figure 2B

Description

Kaplan-Meier digitized data from CBCSG006, figure 2B (PMID 25795409). A reported sample size of 240 for a primary endpoint of PFS in breast cancer.

Usage

CBCSG006_2B

Format

A data frame of 236 observations and 3 variables:

time event time (in months)
event OS event indicator (0: no event, 1: event)
arm treatment arms (cis_gemcitabine, paclitaxel_gemcitabine)

Source

Hu X-C, Zhang J, Xu B-H, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16: 436–46.

Examples

summary(CBCSG006_2B)

kmplot(CBCSG006_2B)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.